Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 randomized double-blind placebo-controlled study of oral RDN-929 in healthy adults and elderly subjects
NL-OMON48190Phase 1Active, not recruiting
- Sponsor
- Rodin Therapeutics
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Alzheimer's disease (AD) comparing RDN-929 with Matching placebo (2 arms). Primary endpoint: Safety and tolerability. Started Oct 2018; status: active, not recruiting.
02
Drugs
RDN-929
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON48190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48190.